Bio-Path Holdings, Inc. (BPTH) Cash Flow Statement
Where BPTH’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$10.6M
- Capital expenditures
- $0
- Free cash flow
- −$10.6M
- Returned to shareholders
- —
- Change in cash
- $121,000 cash at year-end $1.2M
Cash from operations
−$10.6M
Shares issued
+$10.7M
Change in cash
$121,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
BPTH operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
BPTH cash flow trends, 2015–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$5.0M2015 | −$10.6M2024 | — | |
| Capital expenditures | $338,0002015 | $02024 | −100.0% | |
| Free cash flow | −$5.0M2015 | −$10.6M2024 | — | |
| Free cash flow margin | −65,276.9%2016 | −22,959.5%2017 | +42,317.5 pts | |
| Stock-based compensation | $3692015 | $566,0002024 | +125.9%/yr | |
| Dividends paid | $02015 | $02017 | — | |
| Share buybacks (net) | $02015 | $02020 | — | |
| Capex / revenue | 2,600.0%2016 | 1,454.1%2017 | −1,145.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BPTH cash flow by activity
OperatingInvestingFinancingChange in cash
BPTH net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BPTH cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$9.9M | −$16.1M | −$13.9M | −$10.4M | −$10.9M | −$8.6M | −$8.6M | −$7.0M | −$6.8M | −$5.5M |
| Depreciation & amortization | $159,000 | $178,000 | $178,000 | $161,000 | $151,000 | $230,000 | $426,000 | $411,000 | $204,000 | $201,762 |
| Stock-based compensation | $566,000 | $734,000 | $851,000 | $821,000 | $577,000 | $684,000 | $554,000 | $793,000 | $784,000 | $369 |
| Change in working capital | $678,000 | $3.1M | −$2.3M | −$459,000 | −$806,000 | −$676,000 | $871,000 | −$204,000 | −$673,000 | −$107,892 |
| Other non-cash items | −$2.1M | $498,000 | $0 | $0 | $0 | $0 | $608,000 | −$1.9M | −$1.7M | $368,264 |
| Cash from operating activities | −$10.6M | −$11.5M | −$15.1M | −$9.9M | −$11.0M | −$8.4M | −$6.1M | −$8.0M | −$8.1M | −$5.0M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$21,000 | −$70,000 | −$70,000 | −$70,000 | −$17,000 | −$538,000 | −$338,000 | −$338,000 |
| Investments (net) | — | $0 | −$21,000 | −$70,000 | $0 | $0 | −$17,000 | −$538,000 | −$338,000 | — |
| Acquisitions & other investing | — | — | — | $70,000 | $0 | $0 | $17,000 | $538,000 | $338,000 | $0 |
| Cash from investing activities | — | — | — | −$70,000 | −$70,000 | −$70,000 | −$17,000 | −$538,000 | −$338,000 | −$338,000 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Share repurchases & issuance (net) | — | — | — | — | $4.3M | $27.8M | $1.2M | $5.1M | $9.0M | $0 |
| Shares issued | $10.7M | $3.4M | $1.7M | $15.8M | $4.3M | $26.7M | $1.2M | $0 | $0 | $0 |
| Other financing | $0 | −$1.2M | $0 | $4.2M | −$4.3M | −$26.7M | −$1.2M | $0 | $0 | $9.0M |
| Cash from financing activities | $10.7M | $2.2M | $1.7M | $20.0M | $4.3M | $27.8M | $1.2M | $5.1M | $9.0M | $9.0M |
| Summary | ||||||||||
| Net change in cash | $121,000 | −$9.3M | −$13.4M | $10.0M | −$6.7M | $19.4M | −$5.0M | −$3.4M | $521,000 | −$5.0M |
| Cash at end of period | $1.2M | $1.1M | $10.4M | $23.8M | $13.8M | $20.4M | $1.0M | $6.0M | $9.4M | $8.9M |
| Free cash flow | −$10.6M | −$11.5M | −$15.1M | −$10.0M | −$11.0M | −$8.4M | −$6.1M | −$8.5M | −$8.5M | −$5.0M |
| Free cash flow margin | — | — | — | — | — | — | — | −22,959.5% | −65,276.9% | — |
| Capex / revenue | — | — | — | — | — | — | — | 1,454.1% | 2,600.0% | — |
| Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$270,000 | −$976,000 | −$4.6M | −$2.9M | −$2.8M | −$2.1M | −$1.9M | −$3.2M | −$3.4M | −$3.2M | −$4.2M | −$5.3M |
| Depreciation & amortization | $11,000 | $7,000 | $41,000 | $32,000 | $47,000 | $33,000 | $32,000 | $47,000 | $41,000 | $46,000 | $46,000 | $45,000 |
| Stock-based compensation | $5,000 | $27,000 | $28,000 | $108,000 | $127,000 | $128,000 | $141,000 | $170,000 | $180,000 | $178,000 | $170,000 | $206,000 |
| Change in working capital | $259,000 | $455,000 | $4.2M | $1.8M | −$434,000 | −$959,000 | −$369,000 | $2.4M | $994,000 | $266,000 | $731,000 | $1.4M |
| Other non-cash items | −$43,000 | $487,000 | $35,000 | −$389,000 | $132,000 | −$515,000 | −$1.2M | −$538,000 | $343,000 | −$72,000 | $0 | $0 |
| Cash from operating activities | −$38,000 | $0 | −$283,000 | −$1.3M | −$2.9M | −$3.4M | −$3.2M | −$1.0M | −$1.8M | −$2.8M | −$3.3M | −$3.7M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | — | — | — | — | — | — | — | $0 | $0 | — | — |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | $50,000 | $0 | $161,000 | $261,000 | — | $0 | $0 | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $3.5M | $0 | $7.0M | $174,000 | $0 | $1.7M | $0 | $0 |
| Other financing | $0 | $0 | $0 | $1,000 | $0 | −$16,000 | $0 | $0 | $514,000 | $0 | $0 | $0 |
| Cash from financing activities | $50,000 | $0 | $161,000 | $262,000 | $3.5M | −$16,000 | $7.0M | $174,000 | $514,000 | $1.7M | $0 | $0 |
| Summary | ||||||||||||
| Net change in cash | $12,000 | $0 | −$122,000 | −$1.1M | $611,000 | −$3.4M | $3.8M | −$864,000 | −$1.3M | −$1.1M | −$3.3M | −$3.7M |
| Cash at end of period | $12,000 | $0 | $0 | $122,000 | $1.2M | $562,000 | $4.0M | $188,000 | $1.1M | $2.4M | $3.4M | $6.7M |
| Free cash flow | −$38,000 | $0 | −$283,000 | −$1.3M | −$2.9M | −$3.4M | −$3.2M | −$1.0M | −$1.8M | −$2.8M | −$3.3M | −$3.7M |
| Free cash flow margin | — | — | — | — | — | — | — | — | −662.0% | — | — | — |
| Capex / revenue | — | — | — | — | — | — | — | — | 0.0% | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BPTH cash generation
In fiscal 2024 (ended December 31, 2024), Bio-Path generated -$10.6 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$10.6 million. Cash and equivalents rose by $0.1 million over the year.
Related: BPTH income statement, BPTH balance sheet. See the BPTH stock overview for the latest quote and news.
BPTH cash flow FAQ
What is Bio-Path's free cash flow?
Bio-Path's free cash flow was -$10.6 million in fiscal 2024: -$10.6 million of operating cash flow minus $0 of capital expenditures It was -$11.5 million a year earlier..
How much cash does Bio-Path generate from operations?
Bio-Path generated -$10.6 million of cash from operating activities in fiscal 2024.